AR047683A1 - Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos - Google Patents
Pirazoles para el tratamiento de obesidad y trastornos psiquiatricosInfo
- Publication number
- AR047683A1 AR047683A1 ARP050100566A ARP050100566A AR047683A1 AR 047683 A1 AR047683 A1 AR 047683A1 AR P050100566 A ARP050100566 A AR P050100566A AR P050100566 A ARP050100566 A AR P050100566A AR 047683 A1 AR047683 A1 AR 047683A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- groups
- alkyl
- alkyl group
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- -1 trifluoromethylthio, difluoromethoxy Chemical group 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 239000011737 fluorine Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000005968 oxazolinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), y sus sales farmacéuticamente aceptable, donde: R1 representa: a) un grupo alcoxi C1-3 sustituido con uno o más de fluor o un grupo alcoxi C4-6 opcionalmente sustituido por uno o más fluor; b)un grupo de la formula fenil(CH2)pO-, en donde p es 1, 2 o 3, y el anillo fenilo está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z; c) un grupo R5S(O)2O o R5S(O)2NH, en donde R5 presenta un grupo alquilo C1-6 opcionalmente sustituido con uno más fluor; o R5 representa fenilo o un grupo heteroarilo, en donde cada uno está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z o d) un grupo de formula (R6)3Si en donde R6 representa un grupo alquilo C1-6 que puede ser igual o diferente; Ra representa halo, un grupo alquilo C1-3 o un grupo alcoxi C1-3; m es 0, 1, 2 o 3; R2 representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, nitro, ciano o halo; n es 0, 1, 2 o 3; R3 representa: a) un grupo X- Y-NR7R8, donde: X es CO o SO2; Y está ausente o representa NH opcionalmente sustituido con un grupo alquilo C1-3; y R7 y R8 representa de manera independiente: un grupo alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo cicloalquilo C3-15 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo (cicloalquilo C3-15)alquileno C1-3 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo -(CH2)r(fenilo)s, donde r es 0, 1, 2, 3 o 4; s es 1cuando r es 0; de otro modo, s es 1 o 2; y los grupo fenilo están opcionalmente sustituidos de manera independiente con uno, dos o tres grupos representados por Z; un grupo heterocíclico de 5 a 8 miembros saturado, que contiene un nitrogeno y, en forma opcional, uno de los siguientes: oxígeno, azufre o un nitrogeno adicional, donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi o bencilo; un grupo -(CH2)tHet en donde t es 0, 1, 2, 3 o 4, y la cadena alquileno está opcionalmente sustituida con uno o más grupos alquilo C1-3, y Het representa un heterociclo aromático opcionalmente sustituido con uno, dos o tres grupos seleccionados de un grupo alquilo C1-5, un grupo alcoxi C1- 5 o halo; o R7 representa H y R8 se define segun lo descripto con anterioridad; o R7 y R8 junto con el átomo de nitrogeno al cual están unidos representan un grupo heterocíclico de 5 a 8 miembros, saturado o parcialmente insaturado, que contiene un nitrogeno y, en forma opcional, uno de los siguientes: oxígeno, azufre o un nitrogeno adicional; donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi, fluor o bencilo; o b) oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tienilo, furilo u oxazolinilo, donde cada uno está opcionalmente sustituido con 1, 2 o 3 grupos Z; R4 representa H, halo, hidroxi, ciano, un grupo alquilo C1-6, un grupo alcoxi C1-6 o un grupo alcoxi C1-6, alquileno C1-6 que contiene un máximo de 6 átomos de carbono, donde cada uno de los grupos está opcionalmente sustituido con uno o más fluor o ciano; Z representa un grupo alquilo C1-3, un grupo alcoxi 1-3, hidroxi, halo, trifluormetilo, trifluormetiltio, difluormetoxi, trifluormetoxi, trifluormetilsulfonilo, nitro, amino, mono- o di-alquilamino C1-3, alquilsulfonilo, C1-3, alcoxicarbonilo C1-3, carboxi, ciano, carbamoilo, mono- o di-alquilo C1-3 carbamoilo y acetilo; y W representa hidroxi, fluor, un grupo alquilo C1-3, un grupo alcoxi C1-3, amino, mono- o di-alquilamino C1-3, un grupo alcoxicarbonilo C1-6, o una amina heterocíclica seleccionada de morfolinilo, pirrolidinilo, piperidinilo o piperazinilo, donde la amina heterocíclica está opcionalmente sustituida con un grupo alquilo C1-3 o hidroxilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0403779A GB0403779D0 (en) | 2004-02-20 | 2004-02-20 | Therapeutic agents |
GB0420780A GB0420780D0 (en) | 2004-09-18 | 2004-09-18 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047683A1 true AR047683A1 (es) | 2006-02-01 |
Family
ID=34889139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100566A AR047683A1 (es) | 2004-02-20 | 2005-02-17 | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20090149463A1 (es) |
EP (1) | EP1718617B1 (es) |
JP (1) | JP4208925B2 (es) |
KR (1) | KR20060131906A (es) |
AR (1) | AR047683A1 (es) |
AT (1) | ATE440085T1 (es) |
AU (1) | AU2005214130B2 (es) |
BR (1) | BRPI0507786A (es) |
CA (1) | CA2555331C (es) |
DE (1) | DE602005016082D1 (es) |
ES (1) | ES2329915T3 (es) |
HK (1) | HK1095329A1 (es) |
IL (1) | IL177218A0 (es) |
NO (1) | NO20063787L (es) |
RU (1) | RU2375349C2 (es) |
TW (1) | TW200531689A (es) |
UY (1) | UY28752A1 (es) |
WO (1) | WO2005080343A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080146614A1 (en) * | 2004-12-23 | 2008-06-19 | Leifeng Cheng | Therapeutic Agents |
EP1743892A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
GB0516661D0 (en) * | 2005-08-13 | 2005-09-21 | Astrazeneca Ab | Therapeutic agents |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
JP2009541283A (ja) * | 2006-06-20 | 2009-11-26 | アストラゼネカ アクチボラグ | 治療薬 |
CN101472896A (zh) * | 2006-06-20 | 2009-07-01 | 阿斯利康(瑞典)有限公司 | 治疗药剂 |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
CA2673359A1 (en) * | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Cb1 receptor modulators |
ES2586433T3 (es) | 2007-04-11 | 2016-10-14 | Omeros Corporation | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
GB0815134D0 (en) * | 2008-08-19 | 2008-09-24 | Univ Aberdeen | Therapeutic compounds and their use |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
CN102358735B (zh) * | 2011-08-23 | 2013-09-04 | 范如霖 | 低毒性的多头分导药,带羟基或取代羟基的含氮芳环cb1受体抑制剂及其制药用途 |
DE102011055815A1 (de) | 2011-11-29 | 2013-05-29 | Aicuris Gmbh & Co. Kg | Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung |
DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
WO2020114813A1 (en) * | 2018-12-04 | 2020-06-11 | Basf Se | Process for preparation of 5-bromo-1,3-dichloro-2-fluoro-benzene |
CN113816892A (zh) * | 2021-08-27 | 2021-12-21 | 安徽鼎旺医药有限公司 | 一种醋酸巴多昔芬的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2732967B1 (fr) * | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
AU2002331766A1 (en) * | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
ES2379076T3 (es) * | 2002-12-02 | 2012-04-20 | Astellas Pharma Inc. | Derivados de pirazol útiles como inhibidores de COX-I |
-
2005
- 2005-02-16 AT AT05717730T patent/ATE440085T1/de not_active IP Right Cessation
- 2005-02-16 BR BRPI0507786-9A patent/BRPI0507786A/pt not_active IP Right Cessation
- 2005-02-16 AU AU2005214130A patent/AU2005214130B2/en not_active Ceased
- 2005-02-16 DE DE602005016082T patent/DE602005016082D1/de active Active
- 2005-02-16 WO PCT/GB2005/000534 patent/WO2005080343A2/en active Application Filing
- 2005-02-16 JP JP2006553649A patent/JP4208925B2/ja not_active Expired - Fee Related
- 2005-02-16 KR KR1020067019280A patent/KR20060131906A/ko not_active Application Discontinuation
- 2005-02-16 US US10/588,294 patent/US20090149463A1/en not_active Abandoned
- 2005-02-16 RU RU2006130683/04A patent/RU2375349C2/ru not_active IP Right Cessation
- 2005-02-16 ES ES05717730T patent/ES2329915T3/es active Active
- 2005-02-16 EP EP05717730A patent/EP1718617B1/en active Active
- 2005-02-16 CA CA2555331A patent/CA2555331C/en not_active Expired - Fee Related
- 2005-02-17 AR ARP050100566A patent/AR047683A1/es not_active Application Discontinuation
- 2005-02-17 UY UY28752A patent/UY28752A1/es unknown
- 2005-02-18 TW TW094104925A patent/TW200531689A/zh unknown
-
2006
- 2006-08-01 IL IL177218A patent/IL177218A0/en unknown
- 2006-08-24 NO NO20063787A patent/NO20063787L/no not_active Application Discontinuation
-
2007
- 2007-03-06 HK HK07102485.1A patent/HK1095329A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0507786A (pt) | 2007-07-17 |
WO2005080343A3 (en) | 2006-01-12 |
UY28752A1 (es) | 2005-09-30 |
AU2005214130B2 (en) | 2008-03-06 |
EP1718617A2 (en) | 2006-11-08 |
IL177218A0 (en) | 2006-12-10 |
TW200531689A (en) | 2005-10-01 |
ES2329915T3 (es) | 2009-12-02 |
EP1718617B1 (en) | 2009-08-19 |
RU2006130683A (ru) | 2008-04-20 |
RU2375349C2 (ru) | 2009-12-10 |
KR20060131906A (ko) | 2006-12-20 |
WO2005080343A2 (en) | 2005-09-01 |
JP2007523139A (ja) | 2007-08-16 |
JP4208925B2 (ja) | 2009-01-14 |
NO20063787L (no) | 2006-09-19 |
ATE440085T1 (de) | 2009-09-15 |
US20090149463A1 (en) | 2009-06-11 |
DE602005016082D1 (de) | 2009-10-01 |
CA2555331A1 (en) | 2005-09-01 |
HK1095329A1 (en) | 2007-05-04 |
CA2555331C (en) | 2011-01-04 |
AU2005214130A1 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047683A1 (es) | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos | |
AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
AR049487A1 (es) | Compuestos de imidazol sustituidos | |
AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
RS52061B (en) | PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | |
ES2304992T3 (es) | Agentes antibacterianos de 3-aminoquinazolin-2,4-diona. | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
ES2572189T3 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
AR065867A1 (es) | Compuestosde isoxazolina y su uso en el control de plagas | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
AR042659A1 (es) | Derivados de 4-5 diariltiazoles como ligandos de cb-1 | |
ES2333802T3 (es) | Inhibidores no nucleicos de transcriptasa inversa. | |
MXPA05005146A (es) | Indolpiridinio sustituido como compuestos antiinfecciosos. | |
ATE444279T1 (de) | Modulatoren von cannabinoidrezeptoren | |
RS52451B (en) | PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE | |
RS50755B (sr) | Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga | |
JO2668B1 (en) | Isoczazolins for controlling invertebrate insects | |
AR058139A1 (es) | Microbiocidas y fungicidas y metodos de control | |
CO5550450A2 (es) | Derivados de 1-acil-pirrolidina para el tratamiento de infec ciones virales | |
NZ517696A (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors | |
AR055368A1 (es) | Derivados de pirazol, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades neurodegenerativas y la obesidad | |
PE20070041A1 (es) | Amidas de acido pirazolcarboxilico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |